← All trials
NCT04307576
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2020
- Primary completion
- Jun 30, 2027
- Completion date
- Jun 30, 2032
- First posted
- Mar 13, 2020
- Last posted
- Mar 13, 2020
- Enrollment
- 6430
- Arms / groups
- 7 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Karolinska InstituteLead sponsor
- Karolinska InstituteSponsor investigator
- Karolinska InstituteStudy chair
- PfizerCollaborator
- Cancer Research UKCollaborator
- Karolinska InstituteCollaborator
- ServierCollaborator
- The Swedish Research CouncilCollaborator
- Katholieke Universiteit LeuvenCollaborator
- CTC Bio, Inc.Collaborator
- Aamu Pediatric Cancer FoundationCollaborator
- Acreditar - Associação de Pais e Amigos das Crianças com CancroCollaborator
- Fundação Rui Osório de CastroCollaborator
- Gesellschaft fur Padiatrische Onkologie und Hamatologie - GermanyCollaborator
- Grupo Português De Leucemias PediátricasCollaborator
- NordForskCollaborator
- The Swedish Childhood Cancer FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.